Company intelligence / Profile preview

ILEX Oncology Services, Incorporated

San Antonio, Texas, United States

Ownership: Private
Employees: ~300
Development stage: Other

Overview

ILEX developed and brought to market CAMPATH (alemtuzumab, targeting CD52), received FDA and EU approvals, and advanced a broad oncology pipeline (including cytotoxic/cytostatic agents, antibodies, and signal transduction inhibitors) before being acquired by Genzyme. Key clinical milestones included new data and US/EU launches for CAMPATH, and active clinical programs in leukemia, lymphoma, MS, and solid tumors[1][3][4].

Therapeutic areas: OncologyNeurologyEndocrinology
Modalities: Small moleculeMonoclonal antibodyAntibody-based immunotherapySynthetic peptideOther
Industry: Biotech

Partnerships

Schering AGBerlexAbgenix

Beyond the preview

Go deeper on ILEX Oncology Services, Incorporated.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ILEX Oncology Services, Incorporated.

Explore the full profile